IDH2 and acute myeloid leukemia: In addition, a retrospective single-center study on the use of enasidenib in R/R AML patients with IDH2 mutations analyzed outcomes in nine IDH2-mutated patients: four (44%) cases of de novo AML and five (56%) of secondary AML.